全文获取类型
收费全文 | 394312篇 |
免费 | 50582篇 |
国内免费 | 16790篇 |
专业分类
耳鼻咽喉 | 7223篇 |
儿科学 | 8469篇 |
妇产科学 | 7521篇 |
基础医学 | 31802篇 |
口腔科学 | 5832篇 |
临床医学 | 57423篇 |
内科学 | 86962篇 |
皮肤病学 | 10329篇 |
神经病学 | 28301篇 |
特种医学 | 15027篇 |
外国民族医学 | 96篇 |
外科学 | 67109篇 |
综合类 | 34409篇 |
现状与发展 | 117篇 |
一般理论 | 48篇 |
预防医学 | 22288篇 |
眼科学 | 10145篇 |
药学 | 25337篇 |
164篇 | |
中国医学 | 10959篇 |
肿瘤学 | 32123篇 |
出版年
2024年 | 1351篇 |
2023年 | 8004篇 |
2022年 | 9859篇 |
2021年 | 14453篇 |
2020年 | 14188篇 |
2019年 | 9719篇 |
2018年 | 15225篇 |
2017年 | 14162篇 |
2016年 | 14880篇 |
2015年 | 18347篇 |
2014年 | 27937篇 |
2013年 | 27321篇 |
2012年 | 23123篇 |
2011年 | 24876篇 |
2010年 | 21964篇 |
2009年 | 23447篇 |
2008年 | 18614篇 |
2007年 | 16949篇 |
2006年 | 18963篇 |
2005年 | 16308篇 |
2004年 | 11783篇 |
2003年 | 9772篇 |
2002年 | 8827篇 |
2001年 | 9914篇 |
2000年 | 9243篇 |
1999年 | 9714篇 |
1998年 | 7313篇 |
1997年 | 7135篇 |
1996年 | 6161篇 |
1995年 | 5784篇 |
1994年 | 4180篇 |
1993年 | 3072篇 |
1992年 | 3727篇 |
1991年 | 3474篇 |
1990年 | 2766篇 |
1989年 | 2679篇 |
1988年 | 2316篇 |
1987年 | 2061篇 |
1986年 | 1881篇 |
1985年 | 1497篇 |
1984年 | 1066篇 |
1983年 | 930篇 |
1982年 | 763篇 |
1981年 | 619篇 |
1980年 | 559篇 |
1979年 | 573篇 |
1978年 | 489篇 |
1977年 | 527篇 |
1975年 | 377篇 |
1972年 | 393篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
随着腹腔镜肝切除技术的发展与推广,腹腔镜肝切除中的一些难点,如术中出血的控制、解剖性肝切除、巨大肝癌切除、腹腔镜下联合肝脏分割与门静脉支结扎的二步肝切除术(ALPPS)等方面均基本解决。术中超声与荧光染色技术也得到普及。本文就上述问题做一概述,并对腹腔镜肝切除未来发展提出思路,以进一步推动我国腹腔镜肝切除的技术进步。 相似文献
35.
36.
37.
评估玻璃体切割联合内界膜剥除对糖尿病性黄斑水肿(DME)的疗效。方法:回顾性病例对照研究。2014年6月至2017年1月间因糖尿病视网膜病变合并玻璃体积血或增殖病变于温州医科大学附属眼视光医院杭州院区行玻璃体切割手术治疗,且术前或术中经光学相干断层扫描(OCT)检查确诊合并DME的患者31例(33眼)纳入研究。16例(18眼)术中联合内界膜剥除作为剥膜组,15例(15眼)仅接受玻璃体切割手术治疗者作为对照组。所有手术均由同一医师主刀完成。术后1、3个月随访时复查OCT,对比观察黄斑中心厚度(CMT)和视力的术后变化情况。随访中CMT和最佳矫正视力(BCVA)比较采用重复测量方差分析,组间CMT和BCVA比较采用独立样本t检验。结果:手术前,手术后1、3个月2组间比较LogMAR视力总体差异有统计学意义(F=15.93,P<0.001)。术后 1个月时剥膜组BCVA高于对照组(t=2.55,P=0.02),但术后3个月时2组间差异无统计学意义(t=0.82, P=0.42)。手术前,手术后1、3个月CMT总体差异无统计学意义(F=2.85,P=0.065)。术后1、3个月时,剥膜组的CMT均低于对照组,2组间差异均有统计学意义(t=2.24,P=0.03;t=3.79,P=0.001)。术后1个月时,剥膜组有效(与术前比CMT减少20%以上)、无效(变化不超过20%)及恶化(增厚超过 20%)的例数分别为8、6、4例,术后3个月时则分别为11、5、2例,与对照组相比,术后1个月时组间差异无统计学意义(Z=-1.687,P=0.092),术后3个月时剥膜组DME改善有效比例明显高于对照组,组间差异有统计学意义(Z=-2.177,P=0.029)。结论:对于非牵拉性DME,内界膜剥除有助于术后早期DME消退。 相似文献
38.
39.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
40.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文